• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

Eczematous liraglutide eruption managed by dupilumab: A case report.

作者信息

Paganini Claudia, Belcastro Alfredo, Fico Angela, Talamonti Marina, Bianchi Luca, Galluzzo Marco

机构信息

Department of Systems Medicine, University of Rome Tor Vergata, Rome, Italy.

出版信息

JAAD Case Rep. 2024 Sep 2;53:57-59. doi: 10.1016/j.jdcr.2024.08.018. eCollection 2024 Nov.

DOI:10.1016/j.jdcr.2024.08.018
PMID:39430632
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC11488440/
Abstract
摘要
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/e068/11488440/75fcd3c10fcb/gr2.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/e068/11488440/4f8051815d22/gr1.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/e068/11488440/75fcd3c10fcb/gr2.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/e068/11488440/4f8051815d22/gr1.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/e068/11488440/75fcd3c10fcb/gr2.jpg

相似文献

1
Eczematous liraglutide eruption managed by dupilumab: A case report.度普利尤单抗治疗利拉鲁肽所致的湿疹样皮疹：一例报告
JAAD Case Rep. 2024 Sep 2;53:57-59. doi: 10.1016/j.jdcr.2024.08.018. eCollection 2024 Nov.
2
A possible role for dupilumab (Dupixent) in the management of idiopathic chronic eczematous eruption of aging.度普利尤单抗（Dupixent）在老年性特发性慢性湿疹样皮疹管理中的潜在作用。
Dermatol Online J. 2018 Feb 15;24(2):13030/qt55z1f6xh.
3
Intravenous immunoglobulin-induced severe vesicular eczematous eruption successfully treated with narrow band-ultraviolet B therapy.
Photodermatol Photoimmunol Photomed. 2021 Sep;37(5):371-373. doi: 10.1111/phpp.12666. Epub 2021 Feb 19.
4
Successful Treatment of Chronic Actinic Dermatitis with Dupilumab: A Case Report and Review of the Literature.度普利尤单抗成功治疗慢性光化性皮炎：一例报告及文献综述
Clin Cosmet Investig Dermatol. 2021 Dec 30;14:1913-1917. doi: 10.2147/CCID.S342401. eCollection 2021.
5
Treatment of paradoxical eczematous eruption in psoriasis treated with secukinumab: A case report.司库奇尤单抗治疗银屑病后出现矛盾性湿疹样发疹的治疗：一例报告。
Medicine (Baltimore). 2023 Feb 10;102(6):e32844. doi: 10.1097/MD.0000000000032844.
6
[Intravenous immunoglobulin-induced eczematous eruption in autoimmune neuromuscular diseases].[静脉注射免疫球蛋白诱导的自身免疫性神经肌肉疾病中的湿疹样皮疹]
Rinsho Shinkeigaku. 2022 Apr 27;62(4):267-271. doi: 10.5692/clinicalneurol.cn-001681. Epub 2022 Mar 29.
7
Dupilumab use in dermatologic conditions beyond atopic dermatitis - a systematic review.治疗特应性皮炎以外的皮肤科疾病中使用度普利尤单抗：系统评价。
J Dermatolog Treat. 2021 Feb;32(1):19-28. doi: 10.1080/09546634.2019.1689227. Epub 2019 Nov 12.
8
Eczematous eruption after brodalumab successfully treated with guselkumab and dupilumab.布罗达单抗治疗成功后出现湿疹样皮疹，使用古塞库单抗和度普利尤单抗治疗。
Dermatol Ther. 2022 Nov;35(11):e15839. doi: 10.1111/dth.15839. Epub 2022 Sep 23.
9
Baseline skin cytokine profiles determined by RNA in situ hybridization correlate with response to dupilumab in patients with eczematous dermatitis.通过 RNA 原位杂交技术确定的基线皮肤细胞因子谱与湿疹性皮炎患者对度普利尤单抗的应答相关。
J Am Acad Dermatol. 2023 May;88(5):1094-1100. doi: 10.1016/j.jaad.2022.12.052. Epub 2023 Feb 11.
10
Diagnostic testing of eczematous dermatitis with incomplete response to dupilumab.
J Am Acad Dermatol. 2022 Sep;87(3):692-695. doi: 10.1016/j.jaad.2022.03.047. Epub 2022 Mar 31.

引用本文的文献

1
A Closer Look at the Dermatological Profile of GLP-1 Agonists.深入探究胰高血糖素样肽-1受体激动剂的皮肤学特征
Diseases. 2025 Apr 22;13(5):127. doi: 10.3390/diseases13050127.

本文引用的文献

1
Rare cutaneous adverse reactions associated with GLP-1 agonists: a review of the published literature.与 GLP-1 激动剂相关的罕见皮肤不良反应：文献复习。
Arch Dermatol Res. 2024 May 25;316(6):248. doi: 10.1007/s00403-024-02969-3.
2
Letter in response to the case report: "Recalcitrant generalized granuloma annulare treated successfully with dupilumab".对病例报告《度普利尤单抗成功治疗顽固性泛发性环状肉芽肿》的回复信
JAAD Case Rep. 2023 Jul 26;39:152-154. doi: 10.1016/j.jdcr.2023.07.018. eCollection 2023 Sep.
3
GLP-1 Agonists for Weight Loss: Pharmacology and Clinical Implications.
GLP-1 激动剂在减肥中的应用：药理学和临床意义。
Adv Ther. 2023 Mar;40(3):723-742. doi: 10.1007/s12325-022-02394-w. Epub 2022 Dec 24.
4
Adverse drug reactions of GLP-1 agonists: A systematic review of case reports.GLP-1 激动剂的药物不良反应：病例报告的系统评价。
Diabetes Metab Syndr. 2022 Mar;16(3):102427. doi: 10.1016/j.dsx.2022.102427. Epub 2022 Feb 12.
5
Long-acting GLP-1RAs: An overview of efficacy, safety, and their role in type 2 diabetes management.长效 GLP-1RA ：疗效、安全性概述及其在 2 型糖尿病管理中的作用。
JAAPA. 2020 Aug;33(8):3-18. doi: 10.1097/01.JAA.0000669456.13763.bd.
6
Chronic Pruritus Responding to Dupilumab-A Case Series.度普利尤单抗治疗有效的慢性瘙痒——病例系列
Medicines (Basel). 2019 Jun 29;6(3):72. doi: 10.3390/medicines6030072.
7
A successful case of dupilumab treatment for severe uremic pruritus.度普利尤单抗治疗重度尿毒症瘙痒症的成功案例。
JAAD Case Rep. 2019 Apr 3;5(4):339-341. doi: 10.1016/j.jdcr.2019.01.024. eCollection 2019 Apr.
8
Dupilumab for treatment of atopic dermatitis.度普利尤单抗治疗特应性皮炎。
Expert Rev Clin Pharmacol. 2018 May;11(5):467-474. doi: 10.1080/17512433.2018.1449642. Epub 2018 Mar 20.